Watch Demo

Cancer Diagnostics Market Research Report by Diagnostic Type, Indication, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

Cancer Diagnostics Market Research Report by Diagnostic Type, Indication, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030
  • Publish Date:January 2023

  • Number of Pages:152

  • Report ID:6389181

  • Format:PDF

  • Publisher:360iResearch

$ 3949

Summary

Cancer Diagnostics Market Research Report by Diagnostic Type (Biopsy & Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers), Indication, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

The United States Cancer Diagnostics Market size was estimated at USD 38.12 billion in 2022 and expected to reach USD 42.47 billion in 2023, projecting growth at a CAGR of 9.56% to reach USD 79.13 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Cancer Diagnostics Market.

Cumulative Impact of Russia-Ukraine Conflict:

We continuously monitor and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Cancer Diagnostics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Cancer Diagnostics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Cancer Diagnostics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group’s economies and geographies can help gain business acumen for better strategic decision-making. Our market coverage across different industry verticals reveals the hidden truth about the players’ strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Cancer Diagnostics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Diagnostic Type, the market is studied across Biopsy & Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.

Based on Indication, the market is studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.

Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Cancer Diagnostics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Cancer Diagnostics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Cancer Diagnostics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Cancer Diagnostics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Cancer Diagnostics Market, including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Koninklijke Philips N.V., Myriad Genetics, Natera, Inc., Personal Genome Diagnostics Inc., Qiagen NV, Quest Diagnostics, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the United States Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the United States Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the United States Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the United States Cancer Diagnostics Market?

Table of contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer in the U.S.
5.1.1.2. Inclination of consumers towards early diagnosis and treatment
5.1.2. Restraints
5.1.2.1. Limited skilled and trained professionals
5.1.3. Opportunities
5.1.3.1. Technological advancements in cancer diagnostics
5.1.4. Challenges
5.1.4.1. Radiation risk from medical imaging for cancer
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter's Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Cancer Diagnostics Market, by Diagnostic Type
6.1. Introduction
6.2. Biopsy & Cytology Test
6.3. Diagnostic Imaging Test
6.4. Tumor Biomarkers

7. Cancer Diagnostics Market, by Indication
7.1. Introduction
7.2. Blood Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Ovarian Cancer
7.10. Pancreatic Cancer
7.11. Prostate Cancer
7.12. Skin Cancer

8. California Cancer Diagnostics Market
8.1. Introduction

9. Florida Cancer Diagnostics Market
9.1. Introduction

10. Illinois Cancer Diagnostics Market
10.1. Introduction

11. New York Cancer Diagnostics Market
11.1. Introduction

12. Ohio Cancer Diagnostics Market
12.1. Introduction

13. Pennsylvania Cancer Diagnostics Market
13.1. Introduction

14. Texas Cancer Diagnostics Market
14.1. Introduction

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Product Portfolio Analysis, By Key Player
15.5. Competitive Scenario
15.5.1. Merger & Acquisition
15.5.2. Agreement, Collaboration, & Partnership
15.5.3. New Product Launch & Enhancement
15.5.4. Investment & Funding
15.5.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. Abbott Laboratories
16.2. Agilent Technologies Inc.
16.3. Becton Dickinson & Company
16.4. F. Hoffmann-La Roche Ltd
16.5. GE Healthcare
16.6. Hologic Inc.
16.7. Illumina Inc.
16.8. Koninklijke Philips N.V.
16.9. Myriad Genetics
16.10. Natera, Inc.
16.11. Personal Genome Diagnostics Inc.
16.12. Qiagen NV
16.13. Quest Diagnostics
16.14. Siemens Healthcare GmbH
16.15. Thermo Fisher Scientific Inc.

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures

FIGURE 1. UNITED STATES CANCER DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 4. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 6. UNITED STATES CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES CANCER DIAGNOSTICS MARKET DYNAMICS
FIGURE 8. UNITED STATES CANCER DIAGNOSTICS MARKET PORTER'S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 11. UNITED STATES CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY DIAGNOSTIC TYPE, 2030
FIGURE 12. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY & CYTOLOGY TEST, 2018-2030 (USD BILLION)
FIGURE 13. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, 2018-2030 (USD BILLION)
FIGURE 14. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, 2018-2030 (USD BILLION)
FIGURE 15. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 17. UNITED STATES CANCER DIAGNOSTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY INDICATION, 2030
FIGURE 18. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD BILLION)
FIGURE 19. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD BILLION)
FIGURE 20. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2018-2030 (USD BILLION)
FIGURE 21. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD BILLION)
FIGURE 22. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, 2018-2030 (USD BILLION)
FIGURE 23. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD BILLION)
FIGURE 24. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD BILLION)
FIGURE 25. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD BILLION)
FIGURE 26. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD BILLION)
FIGURE 27. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD BILLION)
FIGURE 28. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, 2018-2030 (USD BILLION)
FIGURE 29. CALIFORNIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 30. FLORIDA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 31. ILLINOIS CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 32. NEW YORK CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 33. OHIO CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 34. PENNSYLVANIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 35. TEXAS CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 36. UNITED STATES CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 37. UNITED STATES CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 38. UNITED STATES CANCER DIAGNOSTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022

List of Tables

TABLE 1. UNITED STATES CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 4. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD BILLION)
TABLE 5. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 6. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY & CYTOLOGY TEST, 2018-2030 (USD BILLION)
TABLE 7. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY & CYTOLOGY TEST, BY STATE, 2018-2030 (USD BILLION)
TABLE 8. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, 2018-2030 (USD BILLION)
TABLE 9. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, BY STATE, 2018-2030 (USD BILLION)
TABLE 10. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, 2018-2030 (USD BILLION)
TABLE 11. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, BY STATE, 2018-2030 (USD BILLION)
TABLE 12. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 13. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, 2018-2030 (USD BILLION)
TABLE 14. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 15. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2018-2030 (USD BILLION)
TABLE 16. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 17. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2018-2030 (USD BILLION)
TABLE 18. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 19. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2018-2030 (USD BILLION)
TABLE 20. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 21. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, 2018-2030 (USD BILLION)
TABLE 22. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 23. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, 2018-2030 (USD BILLION)
TABLE 24. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 25. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2018-2030 (USD BILLION)
TABLE 26. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 27. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, 2018-2030 (USD BILLION)
TABLE 28. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 29. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, 2018-2030 (USD BILLION)
TABLE 30. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 31. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, 2018-2030 (USD BILLION)
TABLE 32. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 33. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, 2018-2030 (USD BILLION)
TABLE 34. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY STATE, 2018-2030 (USD BILLION)
TABLE 35. CALIFORNIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 36. CALIFORNIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 37. CALIFORNIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 38. FLORIDA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 39. FLORIDA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 40. FLORIDA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 41. ILLINOIS CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 42. ILLINOIS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 43. ILLINOIS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 44. NEW YORK CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 45. NEW YORK CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 46. NEW YORK CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 47. OHIO CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 48. OHIO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 49. OHIO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 50. PENNSYLVANIA CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 51. PENNSYLVANIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 52. PENNSYLVANIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 53. TEXAS CANCER DIAGNOSTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 54. TEXAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2030 (USD BILLION)
TABLE 55. TEXAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD BILLION)
TABLE 56. UNITED STATES CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 57. UNITED STATES CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 58. UNITED STATES CANCER DIAGNOSTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 59. UNITED STATES CANCER DIAGNOSTICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 60. UNITED STATES CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 61. UNITED STATES CANCER DIAGNOSTICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 62. UNITED STATES CANCER DIAGNOSTICS MARKET MERGER & ACQUISITION
TABLE 63. UNITED STATES CANCER DIAGNOSTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 64. UNITED STATES CANCER DIAGNOSTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 65. UNITED STATES CANCER DIAGNOSTICS MARKET INVESTMENT & FUNDING
TABLE 66. UNITED STATES CANCER DIAGNOSTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 67. UNITED STATES CANCER DIAGNOSTICS MARKET: LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Agilent Technologies Inc.
Becton Dickinson & Company
F. Hoffmann-La Roche Ltd
GE Healthcare
Hologic Inc.
Illumina Inc.
Koninklijke Philips N.V.
Myriad Genetics
Natera, Inc.
Personal Genome Diagnostics Inc.
Qiagen NV
Quest Diagnostics
Siemens Healthcare GmbH
Thermo Fisher Scientific Inc.

Methodology

Our market research methodology is designed to provide the clients with comprehensive and accurate information on various industries and markets. It includes data collection, primary interviews, macro-economic factor analysis, country-level data analysis etc.

The data is gathered from a wide range of sources, including industry reports, government statistics, and company financials. This data is then analyzed and cross-referenced to ensure its accuracy and reliability. Next, primary interviews are conducted with industry experts and key stakeholders to gather their insights and perspectives on the market. This information is then combined with the data collected to provide a complete picture of the market. Macro-economic factor analysis is also carried out to understand the impact of external factors on the market. Finally, country-level data analysis is performed to understand the market dynamics in specific regions and countries.

Reportlinker's market research methodology is designed to provide clients with a clear understanding of the market, its trends, and its future potential.